Thryv Therapeutics

Thryv Therapeutics

  • Founded: 2019
  • Location: Laval, QC
  • Employee range: 1-50
  • Funding: 10-100M

job board

Short description:

Contact us to add description:

Drug notes:

Contact us to add description:

Long description:

Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT syndromes, atrial fibrillation and oncology. Central to Thryv’s approach is the use of SGK1 inhibitors - SGK1 is a protein kinase which regulates a number of ion currents in human cardiac cells and supports cell survival and proliferation in many resistant cancer cells. Thryv has rapidly advanced their portfolio of SGK1 inhibitors and have completed a Phase 1 healthy volunteer study for LQT-1213.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy